Immunotherapy in pediatric acute lymphoblastic leukemia

Area of Science:

• Pediatric Oncology
• Hematology
• Immunotherapy

Background:

• The 5-year survival rate for acute lymphoblastic leukemia (ALL) in high-income countries exceeds 90%.
• Increased chemotherapy intensity is limited by significant adverse effects.
• Novel therapeutic strategies are essential for further improvement.

Purpose of the Study:

• To review recent advances in targeted therapies for ALL.
• To highlight the role of immunotherapy and molecular therapeutics.
• To discuss improvements in risk stratification and minimal residual disease monitoring.

Main Methods:

• Review of recent advancements in targeted therapy, including immunotherapy and molecular therapeutics.
• Analysis of risk stratification based on genetic analysis.
• Evaluation of minimal residual disease monitoring techniques.

Main Results:

• Immunotherapy approvals (blinatumomab, inotuzumab ozogamicin, tisagenlecleucel) have improved outcomes in relapsed/refractory B-ALL.
• Frontline immunotherapy strategies are under investigation.
• Development of immunotherapy targeting new ALL-associated antigens.

Conclusions:

• Immunotherapy integration can decrease conventional chemotherapy intensity and reduce toxicity.
• This approach promises further improvements in survival and quality of life for ALL patients.
• Targeted therapies represent a significant advancement in ALL treatment.